ERBB2 and breast cancer: For example, CDK4/6 (cyclin-dependent kinase 4/6) inhibitors and HER2-targeted drugs (Pertuzumab, Trastuzumab, etc.)have been shown to reduce the risk of recurrence and prolong the survival of patients with early BC (7, 8).